Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total stock-based compensation expense	$ 2,187	$ 1,535
RSUs and Restricted Stock [Member]
Total stock-based compensation expense	176	243
Performance Based Awards [Member]
Total stock-based compensation expense	265
Common stock awards [Member]
Total stock-based compensation expense	116
Option [Member]
Total stock-based compensation expense	$ 1,630	$ 722